dihydroergotamine has been researched along with raltegravir potassium in 1 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Adibi, A; Aliashrafi, M; Ghafouri-Fard, S; Jeibouei, S; Karami, F; Mahdian, S; Mirmotalebisohi, SA; Molavi, Z; Niazi, V; Niknam, Z; Ranjbar, MM; Razi, S; Sameni, M; Taheri, M; Yazdani, M; Zali, H | 1 |
1 other study(ies) available for dihydroergotamine and raltegravir potassium
| Article | Year |
|---|---|
Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Topics: Animals; Antiviral Agents; Coronavirus 3C Proteases; COVID-19; COVID-19 Drug Treatment; Dihydroergotamine; Drug Approval; Drug Repositioning; Enzyme Inhibitors; Host-Pathogen Interactions; Humans; Molecular Docking Simulation; Molecular Dynamics Simulation; Raltegravir Potassium; RNA-Dependent RNA Polymerase; SARS-CoV-2; United States; United States Food and Drug Administration | 2021 |